BioPharmSignal logoBioPharmSignal

Biotech News

Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results

Aptevo Therapeutics (APVO)Aptevo TherapeuticsEarnings

Mipletamig Drives Clinical Momentum with Strong Frontline AML Data, Path Toward Phase 2 Chief Scientific Officer Appointment Strengthens Execution Across Advancing Oncology Pipeline Non-Dilutive Grant Funding Advances APVO451 and Validates Trispecific Solid Tumor Strategy Strategic Niowave

Related news

IMTXImmatics2026-08-18 11:00 EST

Immatics Announces Second Quarter 2026 Financial Results and Business Update

GNLXGenelux2026-08-13 20:20 EST

Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates

MGNXMacroGenics2026-08-13 20:05 EST

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

FATEFate Therapeutics2026-08-13 12:30 EST

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

ERASErasca2026-08-11 20:01 EST

Erasca Reports Second Quarter 2026 Business Updates and Financial Results

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

ZNTLZentalis2026-08-06 20:05 EST

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

CHRSCoherus BioSciences, Inc.2026-08-05 20:28 EST

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

View all latest news

Aptevo Therapeutics

Multispecific Immunotherapy Platforms Aptevo Therapeutics is a clinical-stage biotechnology company developing multispecific immunotherapies for cancer. Its ADAPTIR and ADAPTIR-FLEX platforms are designed to create molecules that engage multiple immune and tumor targets within a single therapeutic construct. Mipletamig Mipletamig is a...

Recent company news

APVOAptevo Therapeutics2026-08-14 12:05 EST

Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results

APVOAptevo Therapeutics2026-08-13 20:05 EST

Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds

APVOAptevo Therapeutics2026-08-12 13:30 EST

Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds

APVOAptevo Therapeutics2026-07-27 12:05 EST

Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone

APVOAptevo Therapeutics2026-06-30 12:05 EST

Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors

Stock data

Close
2.81 USD
Market cap
6.28M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States